Roche Holding AG said Monday that Phase 3 Graduate studies of gantenerumab, for treatment of early Alzheimer’s disease, failed to meet its primary endpoints.
The Swiss pharma company
ROG,
said the drug failed to slow patients’ clinical decline and that the drug’s removal of beta-amyloid, a protein that builds up to make plaques in the brains of people with Alzheimer’s disease, was lower than expected.
The company said it would keep working on novel diagnostics and treatments for Alzheimer’s and said it would present at the Clinical Trials on Alzheimer’s Disease Conference.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
This post was originally published on Market Watch
